$HIMS jumps more than 7% after an FDA panel recommends adding BPC-157 to the 503A compounding list potentially opening a new peptide category. The opportunity fits Hims existing telehealth, compounding and customer acquisition engine. https://t.co/DJPcWDayFZ
View on X ↗